Systematic analysis of direct antiglobulin test results in post-artesunate delayed haemolysis.
Artemisinins
Artesunate
Coombs test
Drug-related side effects and adverse reactions
Hemolytic anemia
Malaria
Journal
Malaria journal
ISSN: 1475-2875
Titre abrégé: Malar J
Pays: England
ID NLM: 101139802
Informations de publication
Date de publication:
29 Apr 2021
29 Apr 2021
Historique:
received:
28
08
2020
accepted:
16
04
2021
entrez:
30
4
2021
pubmed:
1
5
2021
medline:
14
9
2021
Statut:
epublish
Résumé
Post-artesunate delayed haemolysis (PADH) is common after severe malaria episodes. PADH is related to the "pitting" phenomenon and the synchronous delayed clearance of once-infected erythrocytes, initially spared during treatment. However, direct antiglobulin test (DAT) positivity has been reported in several PADH cases, suggesting a contribution of immune-mediated erythrocyte clearance. The aim of the present study was to compare clinical features of cases presenting a positive or negative DAT. Articles reporting clinical data of patients diagnosed with PADH, for whom DAT had been performed, were collected from PubMed database. Data retrieved from single patients were extracted and univariate analysis was performed in order to identify features potentially related to DAT results and steroids use. Twenty-two studies reporting 39 PADH cases were included: median baseline parasitaemia was 20.8% (IQR: 11.2-30) and DAT was positive in 17 cases (45.5%). Compared to DAT-negative individuals, DAT-positive patients were older (49.5 vs 31; p = 0.01), had a higher baseline parasitaemia (27% vs 17%; p = 0.03) and were more commonly treated with systemic steroids (11 vs 3 patients, p = 0.002). Depth and kinetics of delayed anaemia were not associated with DAT positivity. In this case series, almost half of the patients affected by PADH had a positive DAT. An obvious difference between the clinical courses of patients presenting with a positive or negative DAT was lacking. This observation suggests that DAT result may not be indicative of a pathogenic role of anti-erythrocytes antibodies in patients affected by PADH, but it may be rather a marker of immune activation.
Sections du résumé
BACKGROUND
BACKGROUND
Post-artesunate delayed haemolysis (PADH) is common after severe malaria episodes. PADH is related to the "pitting" phenomenon and the synchronous delayed clearance of once-infected erythrocytes, initially spared during treatment. However, direct antiglobulin test (DAT) positivity has been reported in several PADH cases, suggesting a contribution of immune-mediated erythrocyte clearance. The aim of the present study was to compare clinical features of cases presenting a positive or negative DAT.
METHODS
METHODS
Articles reporting clinical data of patients diagnosed with PADH, for whom DAT had been performed, were collected from PubMed database. Data retrieved from single patients were extracted and univariate analysis was performed in order to identify features potentially related to DAT results and steroids use.
RESULTS
RESULTS
Twenty-two studies reporting 39 PADH cases were included: median baseline parasitaemia was 20.8% (IQR: 11.2-30) and DAT was positive in 17 cases (45.5%). Compared to DAT-negative individuals, DAT-positive patients were older (49.5 vs 31; p = 0.01), had a higher baseline parasitaemia (27% vs 17%; p = 0.03) and were more commonly treated with systemic steroids (11 vs 3 patients, p = 0.002). Depth and kinetics of delayed anaemia were not associated with DAT positivity.
CONCLUSIONS
CONCLUSIONS
In this case series, almost half of the patients affected by PADH had a positive DAT. An obvious difference between the clinical courses of patients presenting with a positive or negative DAT was lacking. This observation suggests that DAT result may not be indicative of a pathogenic role of anti-erythrocytes antibodies in patients affected by PADH, but it may be rather a marker of immune activation.
Identifiants
pubmed: 33926462
doi: 10.1186/s12936-021-03735-w
pii: 10.1186/s12936-021-03735-w
pmc: PMC8082776
doi:
Substances chimiques
Antimalarials
0
Artesunate
60W3249T9M
Types de publication
Journal Article
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
206Références
Trop Doct. 2019 Jan;49(1):54-55
pubmed: 30293518
PLoS Med. 2009 Jul 21;6(7):e1000097
pubmed: 19621072
Emerg Infect Dis. 2011 May;17(5):771-7
pubmed: 21529383
Am J Trop Med Hyg. 1999 May;60(5):733-7
pubmed: 10344643
Emerg Infect Dis. 2015 May;21(5):804-12
pubmed: 25898007
Blood. 2001 Jul 15;98(2):450-7
pubmed: 11435316
Malar J. 2014 Oct 11;13:398
pubmed: 25306236
Lancet. 2013 Jul 13;382(9887):180
pubmed: 23849926
Malar J. 2017 Jan 31;16(1):57
pubmed: 28143519
MMWR Morb Mortal Wkly Rep. 2013 Jan 11;62(1):5-8
pubmed: 23302816
Malar J. 2011 Dec 29;10:386
pubmed: 22206234
Travel Med Infect Dis. 2017 Jan - Feb;15:52-56
pubmed: 27818359
Nat Med. 2000 Nov;6(11):1264-8
pubmed: 11062539
Immunol Cell Biol. 1992 Aug;70 ( Pt 4):267-75
pubmed: 1427985
Br J Haematol. 1997 Apr;97(1):169-74
pubmed: 9136961
Malar J. 2012 Mar 31;11:102
pubmed: 22462806
J Infect Dis. 2019 Sep 26;220(9):1435-1443
pubmed: 31250022
Blood. 2014 Jul 10;124(2):167-75
pubmed: 24859359
Malar J. 2012 Mar 27;11:91
pubmed: 22453057
Parasite Immunol. 2011 Feb;33(2):104-15
pubmed: 21226723
Malar J. 2012 May 17;11:169
pubmed: 22594446
Science. 1984 Jan 27;223(4634):400-3
pubmed: 6362007
Curr Drug Saf. 2019;14(1):60-66
pubmed: 30411691
Enferm Infecc Microbiol Clin. 2020 Mar;38(3):139-140
pubmed: 31378562
Anaesth Crit Care Pain Med. 2015 Dec;34(6):365-6
pubmed: 26494308
Infection. 2013 Aug;41(4):863-5
pubmed: 23553281
Blood Rev. 2020 May;41:100648
pubmed: 31839434
J Infect Dis. 2000 Aug;182(2):629-33
pubmed: 10915102
Lancet. 2010 Nov 13;376(9753):1647-57
pubmed: 21062666
Arch Pathol Lab Med. 2017 Feb;141(2):305-310
pubmed: 28134589
PLoS One. 2013;8(3):e60150
pubmed: 23555907
Indian J Crit Care Med. 2018 Oct;22(10):753-756
pubmed: 30405291
Cell Host Microbe. 2016 Feb 10;19(2):194-203
pubmed: 26867178
Malar J. 2012 Apr 27;11:135
pubmed: 22540175
Malar J. 2013 Jul 15;12:241
pubmed: 23855745
Am J Trop Med Hyg. 2001 Nov;65(5):614-22
pubmed: 11716124
Blood. 2006 May 1;107(9):3745-52
pubmed: 16384927
Br J Biomed Sci. 2001;58(1):20-3
pubmed: 11284219
Am J Trop Med Hyg. 2015 Oct;93(4):819-21
pubmed: 26240154
Clin Exp Immunol. 1979 Jan;35(1):119-27
pubmed: 371880
Emerg Infect Dis. 2015 Jan;21(1):164-6
pubmed: 25531800
PLoS One. 2010 Apr 06;5(4):e10038
pubmed: 20386613
Trends Parasitol. 2002 Oct;18(10):458-64
pubmed: 12377597
Malar J. 2015 Jun 18;14:246
pubmed: 26081927
J Infect Chemother. 2018 Mar;24(3):216-219
pubmed: 29127021
J Travel Med. 2018 Jan 1;25(1):
pubmed: 29394387
Am J Trop Med Hyg. 2017 May;96(5):1185-1189
pubmed: 28193740
Blood. 2011 Feb 24;117(8):e88-95
pubmed: 21163923
Blood. 2008 Sep 15;112(6):2520-8
pubmed: 18579796
J Antimicrob Chemother. 2012 Aug;67(8):2053-4
pubmed: 22523307
Sci Rep. 2019 Oct 17;9(1):14940
pubmed: 31624288
Blood. 2014 Jul 10;124(2):157-8
pubmed: 25013158
Lancet. 2005 Aug 27-Sep 2;366(9487):717-25
pubmed: 16125588
Malar J. 2019 Apr 8;18(1):123
pubmed: 30961636
Pathog Glob Health. 2012 Jul;106(3):181-7
pubmed: 23265377
PLoS One. 2014 Feb 13;9(2):e88548
pubmed: 24551116